Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Genome sequencing identifies a basis for everolimus sensitivity.

Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB.

Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

2.

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH.

N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.

3.

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC.

Oncotarget. 2016 Mar 1;7(9):10547-56. doi: 10.18632/oncotarget.7234.

4.

Words of wisdom: Re: Genome sequencing identifies a basis for everolimus sensitivity.

Zlotta AR.

Eur Urol. 2013 Sep;64(3):516. doi: 10.1016/j.eururo.2013.06.031. No abstract available.

PMID:
23915465
5.

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.

Expert Opin Pharmacother. 2011 Oct;12(14):2265-9. doi: 10.1517/14656566.2011.601742. Epub 2011 Aug 1. Review.

6.

Phase II study of everolimus in metastatic urothelial cancer.

Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF.

BJU Int. 2013 Aug;112(4):462-70. doi: 10.1111/j.1464-410X.2012.11720.x. Epub 2013 Apr 3.

7.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

8.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A.

Mol Cancer Ther. 2015 May;14(5):1224-35. doi: 10.1158/1535-7163.MCT-14-0768. Epub 2015 Feb 27.

9.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
10.

Everolimus: a new hope for patients with breast cancer.

Sendur MA, Zengin N, Aksoy S, Altundag K.

Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Review.

PMID:
24050600
11.

Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.

Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, Roué G.

Clin Cancer Res. 2012 Oct 1;18(19):5278-89. doi: 10.1158/1078-0432.CCR-12-0351. Epub 2012 Aug 9.

12.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP.

Ann Oncol. 2012 Oct;23(10):2663-70. Epub 2012 Apr 3.

PMID:
22473592
13.

Phase II study of everolimus in metastatic urothelial cancer.

Smith AB, Pruthi RS.

BJU Int. 2013 Aug;112(4):427-8. doi: 10.1111/j.1464-410X.2012.11717.x. No abstract available.

14.

Everolimus.

Hasskarl J.

Recent Results Cancer Res. 2014;201:373-92. doi: 10.1007/978-3-642-54490-3_23. Review.

PMID:
24756805
15.

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.

Clin Genitourin Cancer. 2014 Aug;12(4):241-50. doi: 10.1016/j.clgc.2013.11.020. Epub 2013 Nov 14.

16.

mTOR as a therapeutic target in patients with gastric cancer.

Al-Batran SE, Ducreux M, Ohtsu A.

Int J Cancer. 2012 Feb 1;130(3):491-6. doi: 10.1002/ijc.26396. Epub 2011 Oct 5. Review.

17.

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.

Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D.

Mol Cancer. 2009 Jun 15;8:38. doi: 10.1186/1476-4598-8-38.

18.

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.

Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.

19.

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.

Ghosh AP, Marshall CB, Coric T, Shim EH, Kirkman R, Ballestas ME, Ikura M, Bjornsti MA, Sudarshan S.

Oncotarget. 2015 Jul 20;6(20):17895-910.

20.

The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.

Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, Bywater MJ, Kinross KM, Astle MV, Waldeck K, Hannan KM, Shortt J, Smyth MJ, Lowe SW, Hannan RD, Pearson RB, Johnstone RW, McArthur GA.

Cancer Discov. 2013 Jan;3(1):82-95. doi: 10.1158/2159-8290.CD-12-0404. Epub 2012 Dec 14.

Supplemental Content

Support Center